Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

Melanoma (stage III or IV) - ipilimumab: review decision - April 2015 information

Melanoma (stage III or IV) - ipilimumab: appendix A - GE decision paper - April 2015 (PDF 77 KB)

Melanoma (stage III or IV) - ipilimumab: review proposal - January 2015 information

Melanoma (stage III or IV) - ipilimumab: appendix B - GE proposal paper - December 2014 (PDF 209 KB)

Melanoma (stage III or IV) - ipilimumab: appendix A - matrix of stakeholders (PDF 99 KB)

Melanoma (stage III or IV) - ipilimumab: equality impact assessment - guidance development (PDF 75 KB)

Melanoma (stage III or IV) - ipilimumab: final appraisal determination information

Melanoma (stage III or IV) - ipilimumab: final appraisal determination guidance (PDF 285 KB)

Melanoma (stage III or IV) - ipilimumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 353 KB)

Melanoma (stage III or IV) - ipilimumab: updated analysis with revised patient access scheme from Bristol Myers-Squibb (PDF 1.54 MB)

Melanoma (stage III or IV) - ipilimumab: revised addendum by Liverpool reviews and implementation group (LRiG) (PDF 504 KB)

Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PAS Submission) (PDF 488 KB)

Melanoma (stage III or IV) - ipilimumab: addendum by Liverpool reviews and implementation group (LRiG) (PDF 302 KB)

Melanoma (stage III or IV) - ipilimumab: consultee and commentator comments on the ACD

Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PDF 1.05 MB)

Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb - supplementary letter (PDF 18 KB)

Melanoma (stage III or IV) - ipilimumab: British Association Skin Cancer Specialist Nurses (PDF 266 KB)

Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists (PDF 67 KB)

Melanoma (stage III or IV) - ipilimumab: Department of Health (PDF 66 KB)

Melanoma (stage III or IV) - ipilimumab: Factor 50 (PDF 88 KB)

Melanoma (stage III or IV) - ipilimumab: Myfanwy Townsend Melanoma Research Fund (PDF 13 KB)

Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing (PDF 60 KB)

Melanoma (stage III or IV) - ipilimumab: Royal College of Pathologists (PDF 6.4 KB)

Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians joint NCRI Melanoma Group/RCR/ACP/JCCO (PDF 302 KB)

Melanoma (stage III or IV) - ipilimumab: Skcin: The Karen Clifford Skin Cancer Charity (PDF 214 KB)

Melanoma (stage III or IV) - ipilimumab: Joint response from Skcin, Factor 50 and the Myfanwy Townsend Melanoma Research (PDF 253 KB)

Melanoma (stage III or IV) - ipilimumab: Liverpool reviews and implementation group (PDF 136 KB)

Melanoma (stage III or IV) - ipilimumab: Dr Paul Lorigan (PDF 57 KB)

Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website

Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website (PDF 787 KB)

Melanoma (stage III or IV) - ipilimumab: MP letters batch 1 (PDF 1.89 MB)

Melanoma (stage III or IV) - ipilimumab: MP letters batch 2 (PDF 2.63 MB)

Melanoma (stage III or IV) - ipilimumab: MP letters batch 3 (PDF 2.56 MB)

Melanoma (stage III or IV) - ipilimumab: parliamentry report (PDF 1.55 MB)

Melanoma (stage III or IV) - ipilimumab: appraisal consultation

Melanoma (stage III or IV) - ipilimumab: appraisal consultation document information

Melanoma (stage III or IV) - ipilimumab: evaluation report

Melanoma (stage III or IV) - ipilimumab: pre-meeting briefing (PDF 378 KB)

Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report

Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report (PDF 1.28 MB)

Melanoma (stage III or IV) - ipilimumab: ERG report - revised table 1 (PDF 37 KB)

Melanoma (stage III or IV) - ipilimumab: Evidence Review Group report - factual accuracy check (PDF 81 KB)

Melanoma (stage III or IV) - ipilimumab: manufacturers submission Bristol Myers-Squibb (PDF 3.72 MB)

Melanoma (stage III or IV) - ipilimumab: clarification

Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 1 (PDF 79 KB)

Melanoma (stage III or IV) - ipilimumab: manufacturer response to the NICE clarification letter 1 (PDF 172 KB)

Melanoma (stage III or IV) - ipilimumab: NICE clarification letter 2 (PDF 77 KB)

Melanoma (stage III or IV) - ipilimumab: manufacturer response to the NICE clarification letter 2 (PDF 8.1 KB)

Melanoma (stage III or IV) - ipilimumab: patient group, professional group and NHS organisation submission statements

Melanoma (stage III or IV) - ipilimumab: British Association of Dermatologists (PDF 85 KB)

Melanoma (stage III or IV) - ipilimumab: Royal College of Nursing (PDF 88 KB)

Melanoma (stage III or IV) - ipilimumab: Royal College of Physicians (PDF 4.7 KB)

Melanoma (stage III or IV) - ipilimumab: Skin Care Campaign (PDF 97 KB)

Melanoma (stage III or IV) - ipilimumab: expert written personal statements

Melanoma (stage III or IV) - ipilimumab: Lorigan (PDF 80 KB)

Melanoma (stage III or IV) - ipilimumab: Nathan (PDF 65 KB)

Melanoma (stage III or IV) - ipilimumab: Jackson (PDF 123 KB)

Melanoma (stage III or IV) - ipilimumab: details of amendments made by ERG to BMS model (PDF 67 KB)

Melanoma (stage III or IV) - ipilimumab: final scope (PDF 53 KB)

Melanoma (stage III or IV) - ipilimumab: final matrix (PDF 64 KB)

Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the draft scope (PDF 141 KB)

Melanoma (stage III or IV) - ipilimumab: responses to consultee and commentators comments on the provisional matrix of consultees and commentators (PDF 39 KB)

Melanoma (stage III or IV) - ipilimumab: equality impact assessment (PDF 43 KB)

Melanoma (stage III or IV) - ipilimumab: draft scope (PDF 56 KB)

Melanoma (stage III or IV) - ipilimumab: provisional matrix (PDF 55 KB)